Novo Nordisk (NVO) fell about 3.5% in U.S. trading as the market kept digesting a negative mix of catalysts that has centered on the company’s next-generation obesity candidate CagriSema and a more cautious multi-year earnings trajectory. Recent sell-side actions—downgrades and sharp price-target cuts—have reinforced the view that Novo must prove it can defend share and pricing power as the GLP-1 market shifts from scarcity-driven growth to coverage, net-price, and differentiation battles. (investing.com)

Sentiment has been pressured since Novo disclosed Phase 3 REDEFINE-4 head-to-head results indicating CagriSema produced less weight loss than Eli Lilly’s tirzepatide (Zepbound/Mounjaro). That performance gap has driven investors to mark down expectations for Novo’s ability to regain momentum with a “next-gen” therapy—especially because the stock’s premium historically depended on clear category leadership in obesity outcomes and rapid growth. (forbes.com)

The decline also comes against management guidance that adjusted sales growth and adjusted operating profit growth could be negative in 2026, with Novo flagging pricing pressure and competition as central headwinds. The shift toward lower net pricing and tougher reimbursement dynamics in the U.S. has become a core bear case, particularly as Lilly scales supply and promotional intensity in obesity while payers push harder on access terms. (biopharmadive.com)

Near-term direction will likely hinge on additional CagriSema and oral/next-generation obesity program updates, plus any evidence that new channel strategies (including telehealth-focused pricing experiments) improve adherence and demand without forcing broader list-price resets. Investors will also watch whether the downgrade cycle stabilizes and whether prescription and market-share trends show Novo can compete on efficacy, access, and convenience at the same time. (axios.com)